Quantitative proteomics analysis of CaMKII phosphorylation and the CaMKII interactome in the mouse forebrain by Baucum, Anthony J. et al.
Quantitative proteomics analysis of CaMKII phosphorylation and 
the CaMKII interactome in the mouse forebrain
Anthony J. Baucum II1,2,5, Brian C. Shonesy1, Kristie L. Rose3, and Roger J. Colbran1,4,5
1Department of Molecular Physiology and Biophysics Vanderbilt University, Nashville, TN 37232
2Department of Biology and Stark Neurosciences Research Institute, Indiana University-Purdue 
University Indianapolis, Indianapolis, IN 46202
3Department of Biochemistry and Mass Spectrometry Resource Center, Vanderbilt University, 
Nashville, TN 37232
4Vanderbilt-Kennedy Center, Vanderbilt University, Nashville, TN 37232
5Vanderbilt Brain Institute, Vanderbilt University, Nashville, TN 37232
Abstract
Ca2+/calmodulin-dependent protein kinase IIα (CaMKIIα) autophosphorylation at Thr286 and 
Thr305/Thr306 regulates kinase activity, modulates subcellular targeting, and is critical for normal 
synaptic plasticity and learning and memory. Here, a mass spectrometry-based approach was used 
to identify Ca2+-dependent and -independent in vitro autophosphorylation sites in recombinant 
CaMKIIα and CaMKIIβ. CaMKII holoenzymes were then immunoprecipitated from subcellular 
fractions of forebrains isolated from either wildtype (WT) mice or mice with a Thr286 to Ala 
knock-in mutation of CaMKIIα (T286A-KI mice) and analyzed using the same approach in order 
to characterize in vivo phosphorylation sites in both CaMKII isoforms and identify CaMKII 
associated proteins (CaMKAPs). A total of 6 and 7 autophosphorylation sites in CaMKIIα and 
CaMKIIβ, respectively, were detected in WT mice. Thr286-phosphorylated CaMKIIα and 
Thr287-phosphorylated CaMKIIβ were selectively enriched in WT Triton-insoluble (synaptic) 
fractions compared to Triton-soluble (membrane) and cytosolic fractions. In contrast, Thr306-
phosphorylated CaMKIIα and Ser315- and Thr320/Thr321-phosphorylated CaMKIIβ were 
selectively enriched in WT cytosolic fractions. The T286A-KI mutation significantly reduced 
levels of phosphorylation of CaMKIIα at Ser275 across all subcellular fractions, and of cytosolic 
CaMKIIβ at Ser315 and Thr320/Thr321. Significantly more CaMKAPs co-precipitated with WT 
CaMKII holoenzymes in the synaptic fraction compared to the membrane fraction, with functions 
including scaffolding, microtubule organization, actin organization, ribosomal function, vesicle 
trafficking, and others. The T286A-KI mutation altered the interactions of multiple CaMKAPs 
with CaMKII, including several proteins linked to autism spectrum disorders. These data identify 
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CaMKII isoform phosphorylation sites and a network of synaptic protein interactions that are 
sensitive to the abrogation of Thr286 autophosphorylation of CaMKIIα, likely contributing to the 
diverse synaptic and behavioral deficits of T286A-KI mice.
Keywords
Synaptic plasticity; postsynaptic density; autophosphorylation; proteomics; mass spectrometry; 
subcellular fractionation; protein-protein interactions
Introduction
The α and β isoforms of Ca2+/calmodulin-dependent protein kinase II (CaMKII) account for 
up to 1–2% of total protein in several regions of mammalian forebrain.1 Studies of 
genetically manipulated mice have revealed critical roles for both CaMKII isoforms in 
regulating synaptic plasticity and behavior.2–8 Both isoforms can be autophosphorylated at 
multiple sites in vitro9–17 with distinct effects on kinase activity and/or on interactions with 
other neuronal proteins. The best understood example is the Ca2+/calmodulin (CaM)-
dependent autophosphorylation of CaMKIIα at Thr286, which generates a Ca2+/CaM-
independent (autonomous) form of the kinase9–11 and enhances CaMKII interactions with 
both Ca2+/CaM and GluN2B subunits of the NMDA-type glutamate receptor.18–20 In 
contrast, CaMKIIα autophosphorylation at Thr305 or Thr306 blocks binding of Ca2+/CaM 
and α-actinin, thereby interfering with kinase activation.13–15, 21 Studies of transgenic 
mouse lines with knock-in mutations at Thr286 or Thr305/6 have demonstrated important 
roles for these two phosphorylation sites in the synaptic targeting of CaMKII, synaptic 
plasticity, and several neurobehaviors.22–26
While the “classical” view is that CaMKII activation is critical for long-term potentiation 
(LTP) of synaptic transmission, more recent studies suggest a more complex picture. For 
example, CaMKIIα is required for long-term depression (LTD) in cerebellar Purkinje 
neurons, whereas CaMKIIβ is required for LTP.2, 7 Moreover, recent studies show that 
CaMKIIα (and Thr286 autophosphorylation) is required for different forms of long-term 
depression in the hippocampus, in addition to the classical role in LTP27, 28. These findings 
emphasize the lack of detailed understanding of CaMKII interactions, targeting, and 
function in neurons, and of the inter-relationships and roles of CaMKIIα and CaMKIIβ 
autophosphorylation sites in vivo.
Here, we analyze mouse forebrain CaMKII holoenzymes using unbiased mass spectrometry-
based approaches to identify CaMKIIα/β phosphorylation sites and CaMKII-associated 
proteins (CaMKAPs). We found that CaMKII holoenzymes isolated from different 
subcellular fractions of wild-type (WT) mice are differentially phosphorylated and interact 
with distinct networks of over 100 known and novel CaMKAPs, many having established 
roles in modulating synaptic structure and function. Parallel analyses in mice with a Thr286 
to Ala knock-in mutation of CaMKIIα (T286A-KI mice) revealed changes in levels of 
phosphorylation at other sites in CaMKIIα and CaMKIIβ, and in the relative levels of co-
precipitating CaMKAPs, which presumably contribute to the synaptic plasticity deficits and 
multiple behavioral phenotypes of these mice.22, 26 In combination, these data provide novel 
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unbiased insights into the regulation, function and subcellular targeting of CaMKII and into 
the deficits in specific downstream molecular signaling pathways.
Results and Discussion
Analysis of in vitro autophosphorylation sites in CaMKIIα and CaMKIIβ
Recombinant CaMKIIα was purified from insect cells and then incubated under three 
conditions. 1) control conditions in the absence of ATP (basal); 2) to allow 
autophosphorylation in the presence of Ca2+/calmodulin alone (Ca2+/CaM); 3) to allow 
autophosphorylation first in the presence of Ca2+/calmodulin and then following Ca2+ 
chelation with EGTA to dissociate calmodulin (Ca2+/CaM then EGTA; sequential) (see 
Materials and Methods for details). Similar conditions were used to identify the preferential 
autophosphorylation of CaMKIIα at Thr286 in the presence of Ca2+/calmodulin, and at 
Thr305 or Thr306 and Ser314 in the presence of EGTA.9–15 However, the full repertoire of 
sites phosphorylated under these conditions is poorly understood. Our MS-based analyses 
recovered tryptic peptides covering >93% of the entire amino acid sequence of CaMKIIα 
under each condition (Fig 1A–1C) and detected a total of 19 residues that were 
phosphorylated in at least one sample, 16 of which were detected only following in vitro 
autophosphorylation (Fig 1D and Table S1). MS/MS spectra for each non-phosphorylated 
and phosphorylated tryptic peptide were confirmed and annotated (Fig S1). The 
chromatographic retention, percent phosphorylation, and PPM mass error of each peptide is 
shown in Table S1.
Since CaMKIIβ autophosphorylation has not been characterized extensively, we used the 
same approach to identify phosphorylation sites in purified recombinant CaMKIIβ (Fig 1A–
C, 1E), yielding ~80% amino acid sequence coverage across the three incubation conditions. 
A total of 15 phosphorylation sites on CaMKIIβ were phosphorylated in at least one sample, 
with 13 sites detected only following in vitro autophosphorylation (Fig 1E, Table S2, Fig 
S2).
Comparison of in vitro autophosphorylated CaMKIIα and CaMKIIβ under different 
conditions
In order to compare relative levels of phosphorylation at each site under each condition, we 
estimated relative phosphorylation stoichiometries from the areas under the curve (AUC) of 
extracted ion chromatograms (XICs) for each phosphorylated and non-phosphorylated 
peptide pair. This approach provides a relatively crude estimate of the absolute levels of 
phosphorylation at each site (see Methods), so our interpretations are focused on relative 
differences between the preincubation conditions. As expected, the homologous Thr286 and 
Thr287 sites in CaMKIIα and CaMKIIβ, respectively, appeared to be substantially 
autophosphorylated in the presence of Ca2+/CaM. Additional Ca2+-independent incubation 
(plus EGTA) appeared to decrease the levels of Thr286/Thr287 phosphorylation, perhaps 
reflecting a lack of precision of this type of analysis. However, this decrease may also be 
due to dephosphorylation in the presence of EGTA due to a previously reported auto-
catalytic event,29 or a contaminating phosphatase. The Ca2+-independent reaction also 
selectively increased phosphorylation of CaMKIIα at Thr306 and Ser314, confirming 
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previous reports.14 Prior studies using site-directed mutagenesis indicated that both Thr305 
and Thr306 in CaMKIIα could be phosphorylated in the Ca2+-independent phase,14, 15 but 
we detected only low levels of Thr305 phosphorylation, and then only when this tryptic 
fragment was also phosphorylated at Thr310 (Table S1). The Ca2+-independent phase of 
CaMKIIβ autophosphorylation (plus EGTA) selectively enhanced modifications at Thr306, 
Thr307, Thr311, and Ser315 (Fig 1 and Table S1, S2). Similar to the homologous CaMKIIα 
Thr305 site, CaMKIIβ phosphorylation at Thr306 was only detected in the simultaneous 
presence of Thr311 phosphorylation (Fig 1E and Table S2). However, these data cannot 
exclude the possibility that Thr305(α) or Thr306(β) can be phosphorylated alone. 
Interestingly, substantial CaMKIIβ phosphorylation at Ser315 was detected only following 
Ca2+-independent autophosphorylation, whereas phosphorylation of CaMKIIα at the 
homologous Ser314 residue was detected in all three samples, presumably due to basal 
phosphorylation of this site in the insect cell expression system prior to purification.
In addition to several previously identified in vitro autophosphoryation sites in both 
CaMKIIα (Thr253, Ser275, Ser279) and CaMKIIβ1 (Ser280, Ser343, Thr382/
Thr383),9, 13, 16, 17 we detected autophosphorylation of CaMKIIα at several novel sites in 
the catalytic domain (e.g., Ser78 and Thr261), as well as at Ser331 and Thr378 in the C-
terminal association domain. We did not detect CaMKIIβ autophosphorylation in the 
catalytic domain, but the association domain was prominently autophosphorylated at 8 
previously unidentified sites. Most of the novel CaMKIIβ phosphorylation sites (Thr320/1, 
Thr325, Ser327, Ser359, Ser368, Thr372, and Thr382/3) are located within two domains 
implicated in F-actin binding (residues 317–342 and 354–393),8 and are not conserved in 
CaMKIIα (Fig S3). Notably, Thr320/1 in CaMKIIβ appeared to be phosphorylated 
predominantly in the Ca2+-independent reaction (plus EGTA). However, even though the 
recombinant CaMKII isoforms used for these studies were highly purified (see Methods), 
we cannot completely exclude contributions of contaminating kinases to total CaMKIIα/ β 
phosphorylation under these conditions.
In combination, these in vitro data confirm that Thr286 in CaMKIIα and Thr287 in 
CaMKIIβ are among several sites phosphorylated in the presence of Ca2+/CaM and also 
indicate that the predominant sites of Ca2+-independent autophosphorylation are Thr306 and 
Ser314 in CaMKIIα and Thr307, Ser315 and Th320/1 in CaMKIIβ. However, they also 
identify several additional sites that can be autophosphorylated under these in vitro 
conditions.
Phosphorylation of CaMKII in subcellular fractions from WT mouse brain
Having established methods to detect phosphorylation sites in purified CaMKIIα and 
CaMKIIβ, we analyzed mouse forebrain CaMKII holoenzymes isolated by 
immunoprecipitation in the presence of protease and protein phosphatase inhibitors from 
cytosolic (S1), Triton-soluble (membrane; S2), and Triton-insoluble (synaptic; S3) fractions 
that were rapidly prepared using progressively harsher detergents at approximately 
physiological ionic strength.26 Following SDS-PAGE, bands containing CaMKIIα or 
1The version of rat CaMKIIβ expressed for these studies has an alanine inserted at position 341 compared to the canonical rat 
CaMKIIβ sequence (accession number: P08413), increasing residue numbering by 1 after this site.
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CaMKIIβ (~50 and ~60 kDa, respectively) were excised (Fig 2A), separately digested with 
trypsin, and then analyzed by LC-MS/MS. Relative levels of phosphorylation at each site 
between subcellular fractions were compared based on the ratio of AUCs for the XICs of 
phosphorylated and non-phosphorylated tryptic peptides (see Methods).
Coverage of CaMKIIα varied from 45–93% across the three fractions in four biological 
replicates (projects A–D; Supplementary Table S4), detecting a total of six phosphorylation 
sites with estimated ratios ranging from 0.1–11.4% (Ser275, Thr286, Thr306, Ser314, 
Ser331, and Thr337). Ser275, Ser314, and Ser331 were phosphorylated at similar levels in 
all three subcellular fractions (Fig 2B). However, the level of Thr286 phosphorylation in 
synaptic fractions was 5-fold or 2.4-fold higher than detected in the cytosolic or membrane 
fractions, respectively (Fig 2B). Differential Thr286 phosphorylation of CaMKIIα between 
subcellular fractions was confirmed by immunoblotting using a phospho-Thr286 specific 
antibody (Fig 2C). Notably, the selective enrichment of Thr286-autophosphorylated 
CaMKIIα in synaptic fractions is generally consistent with prior studies showing that 
Thr286 autophosphorylation enhances synaptic targeting of CaMKIIα26, 30, 31 In contrast, 
levels of Thr306 phosphorylation were >6-fold higher in the cytosolic kinase relative to 
membrane or synaptic pools of kinase (Fig 2B). These data are consistent with previous 
observations that Thr305/306 phosphorylation destabilizes synaptic targeting of 
CaMKIIα.23, 30 It is interesting that CaMKIIα was predominantly phosphorylated at Thr306 
rather than Thr305, because phosphorylation at Thr306, but not at Thr305, blocks the 
CaMKII interaction with α-actinin-2,21 a major synaptic F-actin-binding protein. Taken 
together, these data show that distinct subcellular pools of CaMKIIα are phosphorylated in a 
site-specific manner.
Mouse forebrain CaMKIIβ was phosphorylated at 7 sites (Thr287, Ser315, Thr320/Thr321, 
Ser367, Thr381/Thr382, Ser397, and Thr401), with estimated ratios varying from 0.4–
54.0%. Alternative mRNA splicing, mostly in the C-terminal domain, generates several 
CaMKIIβ variants, and our data cannot address whether these variants are differentially 
phosphorylated at sites in the conserved domains. Therefore, all CaMKIIβ residues are 
numbered according to the major, canonical, CaMKIIβ isoform (Accession # P28652). 
Somewhat surprisingly, we did not detect significant phosphorylation of CaMKIIβ at Thr306 
or Thr307 in any subcellular fraction. Levels of phosphorylation at Ser367, Ser397, and 
Thr401 were not significantly different between subcellular fractions (Fig 2D), but there was 
a trend for enrichment of Thr287 phosphorylation in synaptic CaMKIIβ, as noted for Thr286 
phosphorylation of CaMKIIα (see above). However, phosphorylation at multiple sites was 
selectively enriched in cytosolic CaMKIIβ. Specifically, levels of Ser315 and Thr320/
Thr321 phosphorylation in cytosolic CaMKIIβ were >5-fold and >9-fold higher, 
respectively, than in the membrane or synaptic kinases (Fig 2B). Thr381/Thr382 
phosphorylation was detected in only one replicate, but levels were >7-fold higher in the 
cytosolic fraction compared with membrane and synaptic fractions. Although we could not 
unambiguously distinguish modifications at Thr320/Thr321 or Thr381/Thr382, these sites 
lie within previously defined F-actin binding domains (Fig. 2E).8 Thus, it seems reasonable 
to suggest that phosphorylation of these sites modulates CaMKIIβ binding to F-actin, and 
thereby F-actin assembly and dendritic spine morphology/function.3, 32–35 In combination, 
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these data show that distinct subcellular pools of CaMKIIβ are differentially phosphorylated 
at specific sites.
All of the phosphorylation sites that we detected in mouse brain CaMKII isoforms were also 
identified as in vitro autophosphorylation sites. However, we cannot exclude potential 
contributions of other protein kinases to CaMKII phosphorylation in vivo. Fig. 2E integrates 
data from our in vitro and in vivo studies with the repertoire of CaMKIIα and CaMKIIβ 
phosphorylation sites that have been identified in previous global mouse brain proteomics 
studies.36–41 Even though our total coverage of both CaMKII isoforms was high (32–93% 
depending on fraction, genotype and replicate), we detected a more limited number of in 
vivo sites than detected in the prior studies or in vitro. Notably, whereas prior studies 
detected phosphorylation of several additional sites in some tryptic fragments, we identified 
a more limited number of sites in the same tryptic fragments (Fig. 2E). The lower sensitivity 
of our in vivo studies relative to the in vitro studies may reflect a lower efficiency of 
digestion/extraction of the kinase from polyacrylamide gels versus TCA precipitates, or ion 
suppression from peptides derived from co-immunoprecipitated proteins. Moreover, the 
greater sensitivity of prior in vivo studies likely reflects the use of metal affinity-based 
methods to enrich for phosphopeptides. Nevertheless, the present study provides new 
insights into CaMKII biology by demonstrated that specific sites are differentially 
phosphorylated between subcellular fractions.
Surprisingly, we failed to detect some previously well-characterized autophosphorylation 
sites in vivo. For example, CaMKIIα phosphorylation at Thr253 in vivo was detected in 
prior proteomics studies,36–39, 42, 43 and using phospho-site specific antibodies.17, 44 
However, we failed to detect phosphorylation of CaMKIIα at Thr253 or of CaMKIIβ at 
Thr254 in samples from mouse brain, even though in vitro Thr253 phosphorylation was 
readily detected (Fig. 1D). Perhaps the phosphorylation stoichiometry was relatively low in 
our in vivo samples because Thr253 phosphorylation is favored under physiological or 
pathophysiological conditions that were not prevalent prior to, or during, tissue isolation. 
Alternatively, the phospho-Thr253 peptide may contain an additional unknown covalent 
modification that affects its mass, so that it could not be identified. Similarly, even though 
commercially available antibodies raised to phospho-Thr305 in CaMKIIα can detect 
CaMKIIα phosphorylation in the brain, we detected substantial phosphorylation at Thr306, 
but not at Thr305. Thus, data obtained using phospho-Thr305 antibodies should be 
cautiously interpreted because it is unclear whether these antibodies consistently detect 
phospho-Thr306 in CaMKIIα.
Effect of T286A-KI mutation on CaMKII phosphorylation in mouse brain
CaMKII holoenzymes isolated from T286A-KI mouse forebrain subcellular fractions were 
analyzed in parallel with WT samples discussed above. There was a robust effect of the 
T286A-KI genotype (p<0.0001) to reduce Ser275 phosphorylation by >90% in all three 
subcellular fractions (Fig 3A). These data suggest that Ser275 phosphorylation may require 
prior phosphorylation at Thr286, although it is unclear whether Ser275 phosphorylation 
results from autophosphorylation (Fig. 1D), or from PKC phosphorylation.45 We also found 
that the T286A-KI mutation decreased Ser314 phosphorylation by 27–47% across the three 
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subcellular fractions (p=0.0003) (Fig 3C), perhaps because the lack of Thr286 
phosphorylation reduces autonomous CaMKII activity. However, there was no effect of 
genotype on CaMKIIα phosphorylation at Thr306, with similar enrichment in cytosolic 
CaMKII holoenzymes in both T286A-KI and WT mice (p<0.0001) (Fig 3B). In addition, 
genotype or fractionation effects on CaMKIIα phosphorylation at Ser331 (Fig 3D) or 
Thr337 were not detected (Fig 3E).
The T286A-KI genotype had a significant effect on, and a significant interaction with 
subcellular fraction, on CaMKIIβ phosphorylation at Ser315 (fraction, p<0.0001; genotype, 
p<0.0001; interaction, p<0.0001; Fig 3G) and Thr320/Thr321 (fraction, p<0.0001; genotype, 
p<0.0145; interaction, p<0.0206; Fig 3H), with decreased levels in T286A-KI cytosolic 
fractions compared to WT cytosolic fractions (by 59.5% and 49.0%, respectively). 
Moreover, in the one biological replicate that detected phosphorylation at Thr381/Thr382, 
the levels were 3.2-fold higher in the WT cytosolic fraction that in the T286A-KI fraction. 
However, there was no statistically significant effect of genotype or fractionation on 
CaMKIIβ phosphorylation at Thr287 (Fig 3F), Ser367 (Fig 3I), Ser397 (Fig 3J), or Thr401 
(Fig 3K).
In combination, these data show that abrogation of Thr286 phosphorylation in CaMKIIα by 
the T286A-KI mutation affects the levels of phosphorylation at other sites in CaMKIIα and 
in CaMKIIβ in different subcellular fractions, perhaps representing some form of 
compensatory adaptation to the disruption of synaptic CaMKII targeting in T286A-KI mice 
and also suggesting previously unrecognized functional linkages between sites. Further 
studies are required to investigate the contributions of these sites to CaMKII regulation, and 
perhaps to the phenotypes of T286A-KI mice.
Characterization of CaMKII associated proteins (CaMKAPs)
We also performed an unbiased proteomic screen for CaMKAPs associated with cytosolic, 
membrane, and synaptic CaMKII holoenzymes. Although the precise macromolecular 
nature of the solubilized synaptic fraction is unclear, we previously showed that it is highly 
enriched in PSD marker proteins, such as PSD95, NMDAR subunits, and other cytoskeletal 
proteins.26 CaMKII holoenzymes were immunoprecipitated from each subcellular fraction 
and then separated by SDS-PAGE. Control samples were isolated from each fraction in 
parallel using a non-specific IgG. CaMKII (α or β) or CaMKAP (non-CaMKII, non-IgG 
regions) regions of the gel lanes (Fig 2A) were excised and separately analyzed using a 
shotgun LC-MS/MS approach.
The total numbers of mass spectra (spectral counts) matching all proteins in analyses of WT 
CaMKII or IgG control samples isolated from cytosolic, membrane, and synaptic fractions 
were used to calculate WT/IgG ratios of 1.2, 4.3, and 5.0, respectively, for the first 
biological replicate (project A) (Table S3). Thus, CaMKII immunoprecipitation from 
cytosolic fractions lacks specificity, perhaps in part due to the lack of detergent in these 
samples. Consequently, subsequent analyses focused on membrane and synaptic fractions. 
CaMKII-derived spectral counts were 2.9-fold higher in membrane compared to synaptic 
fractions (Fig 4A), consistent with immunoblotting and protein staining data showing higher 
total levels of CaMKII in membrane, compared to synaptic, fractions (Fig 2A, 2C). In 
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contrast, the total number of CaMKAP-derived spectral counts was 3.2-fold higher in the 
synaptic fraction compared to the membrane fraction (Fig 4B), even though the harsher 
solubilization conditions might destabilize some protein-protein interactions. Thus, it 
appears that CaMKAPs are preferentially associated with synaptic CaMKII holoenzymes. 
Unsurprisingly, most of the non-CaMKII derived spectral counts were detected in analyses 
of the two CaMKAP gel regions (above CaMKIIβ and below CaMKIIα), although a few co-
precipitating proteins were detected in CaMKIIα or CaMKIIβ gel regions. Similar trends in 
the spectral count data were observed in two independent biological replicates (Projects B 
and D) (Fig S4; Table S3).
All proteins detected in CaMKII complexes for all three projects are shown in Table S3. 
This list was then filtered to remove three types of “non-specific” proteins. 1. Proteins also 
detected in the cytosolic fraction (due to the lack of specificity; see above). 2. Proteins 
detected with <7 spectral counts in membrane and synaptic fractions combined. 3. Proteins 
with WT/IgG spectral count ratios of <4 (since a WT/IgG ratio of 3.8 was calculated for 
CaMKIIα-derived spectral counts in the synaptic fraction). Remaining proteins from the 
three independently analyzed gel regions were then combined to form a final filtered list of 
138 CaMKAPs (Table 1). Scaffold peptide probability46 and XCorr values for all peptides 
matching to any of the 138 CaMKAPs are shown in Table S4. The membrane and synaptic 
fractions contained 47 and 110 CaMKAPs, respectively, with ≥7 spectral counts (Fig 4C), 
and 34 CaMKAPs were detected with <7 spectral counts in either fraction, individually, but 
≥ 7 total spectral counts in both fractions combined. Based on the number of spectral counts, 
a total of 15 CaMKAPs were selectively enriched in the membrane CaMKII complex, 
whereas 93 CaMKAPs were selectively enriched in the synaptic CaMKII complex, with 30 
showing little selectivity (≤ 2-fold difference in number of spectral counts between the two 
fractions). About half of the CaMKAPs identified in Project A were also detected in at least 
one of the two independent replicates (Projects B and D) (Table S3). Note that our definition 
of CaMKAPs as proteins that specifically co-precipitate with CaMKII is not intended to 
imply direct binding to CaMKII, because CaMKII holoenzymes may be components of 
large multiprotein complexes. However, CaMKAPs may be important downstream targets 
whether or not they directly interact with CaMKII.
Several synaptic CaMKAPs identified here were previously shown to directly interact with 
CaMKII, validating our approach. For example, NMDA receptor subunits (GluN1, GluN2B, 
and GluN2A), densin (LRRC7), spinophilin (PPP1R9b; neurabin-2), and myosin Va can 
directly bind CaMKII and modulate kinase activity and/or subcellular 
localization.19–21, 47–51 CaMKII interaction with GluN2B was recently shown to be 
important for normal synaptic plasticity.52–54 However, some previously characterized 
CaMKAPs were either undetected (e.g., diacylglycerol lipase-α55) or did not meet our 
rigorous cutoffs (e.g., α-actinin21). This may be due to dissociation of the interacting protein 
from CaMKII during subcellular fractionation, weakness of the interaction in the tissue 
analyzed here, or low abundance. Moreover, some weaker interactions may be easier to 
detect when the CaMKAP, rather than CaMKII, is immunoprecipitated (e.g., diacylglycerol 
lipase-α55). However, most CaMKAPs detected here have not been previously reported to 
associate with CaMKII, including several synaptic scaffolding proteins (e.g., SAPAP1/2/3/4, 
Shank1/2/3, and Brain-enriched guanylate kinase-associated protein) and proteins with other 
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functions (e.g., brain-specific angiogenesis inhibitor 1-associated protein 2 (BAIAP2)); TNF 
receptor-associated factor 3; multiple subunits of phosphorylase b kinase; Limbic system-
associated membrane protein; Eukaryotic initiation factor 4A (eIF4A); and 
phosphodiesterase 1. Additional studies will be required to ascertain whether these novel 
CaMKAPs directly bind to CaMKII, or are components of larger macromolecular 
complexes.
To provide initial insight into functionally related groupings and roles of the CaMKAPs, the 
STRING database of mouse proteins, containing all but one CaMKAP (SynGAP), was used 
to assign CaMKAPs into 14 groups based on known associations and functions (CaMKII; 
NMDARs; synaptic scaffolds; myosins; tubulin and microtubules; actin cytoskeleton; 
ribosome and translation; ATPase/GTPase; metabolism and mitochondria; junction and 
myelin; general signaling, intermediate filaments; vesicle trafficking; and other) (Fig. 5). 
The top Kyoto Encyclopedia of Genes and Genomes (KEGG; www.kegg.jp56) pathways in 
this network were then identified using WebGestalt57, 58 (Table S5), including Ca2+ 
signaling, long-term potentiation, and the ribosome. Taken together, these analyses 
emphasize that CaMKII is involved in diverse pathways in multiple cellular compartments. 
However, additional studies will be required to identify specific functional roles of the 
interactions.
Effect of the T286A-KI mutation on CaMKII interactions
In order to provide additional perspective about the biological relevance of CaMKAPs, we 
isolated and analyzed in parallel synaptic CaMKII complexes from WT and T286A-KI 
mice. Since T286A-KI mice display robust changes in synaptic plasticity and diverse 
behavioral deficits,22, 26 we hypothesized that changes in the CaMKII interactome would 
provide insights into molecular mechanisms underlying behavioral and synaptic phenotypes. 
Consistent with a prior observation that synaptic levels of CaMKIIα are reduced in T286A-
KI mice relative to WT,26 the number of CaMKII spectral counts in synaptic T286A-KI 
complexes were reduced by ~33% relative to WT complexes. Therefore, to provide an initial 
semi-quantitative comparison of the relative levels of CaMKAPs associated with CaMKII 
holoenzymes in WT and T286A-KI synaptic fractions, we normalized the number of 
CaMKAP spectral counts to the number of CaMKII spectral counts (all isoforms), and then 
expressed normalized values as a KI/WT ratio. KI/WT ratios of between 0.6 and 1.4 for the 
majority (10 out of 18) of CaMKAPs, indicated minimal changes in relative association. 
However, average KI/WT ratios across two biological replicates were ≥1.40 for eIF4A, 
GluN1, GluN2B, PSD-95, SAPAP1, SAPAP2, and Shank3, but less than 0.6 for only one 
CaMKAP, BAIAP2 (Table 2).
We also compared relative levels of CaMKII and CaMKAPs in WT and T286A-KI synaptic 
complexes by measuring AUCs of XICs for several peptides. In project A, this analysis 
indicated that levels of CaMKIIα and CaMKIIβ in T286A-KI complexes were 46.4±5.1% (9 
peptides) and 57.3±13.8% (7 peptides) of the levels in WT complexes, respectively. In 
project B, levels of CaMKIIα in T286A-KI complexes were 49.5±4.7% (9 peptides) of the 
levels in WT complexes (CaMKIIβ was not analyzed in this project). Raw AUCs of XICs 
for 2–9 peptides matching each CaMKAP were then normalized to the mean CaMKIIα 
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AUC of XIC in the same project, before calculating a KI/WT ratio. KI/WT ratios were 
significantly greater than 1.0 for GluN2B, GluN1, Shank3, PSD-95, and SAPAP1 in both 
projects A and B (Fig. 6A–E), generally similar to KI/WT ratios calculated from spectral 
counts (see above), with the exception of SAPAP2 (Fig 6F; Table 2). As a control, KI/WT 
ratios for myosin Va were not significantly different from 1.0 by AUC analysis in either run 
(Fig. 6I), consistent with the KI/WT ratio based on spectral counts (Table 2). A KI/WT ratio 
for eIF4A could be calculated in only one biological replicate because relevant MS/MS 
spectra could not be validated in the other analysis. The 4.5-fold increase in mean KI/WT 
ratio for eIF4A based on AUCs was consistent with the 7.5-fold increase based on spectral 
counts, although the increased AUC-based ratio was not statistically significant (Fig 6G). In 
contrast, mean AUC-based KI/WT ratios for BAIAP2 were significantly decreased in both 
projects (Fig 6H), consistent with KI/WT ratios based on spectral counts.
These independent analytical approaches indicate that T286A-KI mutation of CaMKIIα 
significantly affects an array of protein-protein interactions in S3 synaptic fractions. Since 
Thr286 autophosphorylation stabilizes direct interactions of CaMKII with GluN2B in 
vitro,19, 20 it is perhaps surprising that we detected a significant increase in KI/WT ratio for 
GluN2B. However, this observation is consistent with a previous analyses of NMDAR 
subunits association with synaptic CaMKII holoenzymes in T286A-KI mice by Western 
blotting.26 We also detected significant increases in KI/WT ratios for several other 
CaMKAPs (e.g., GluN1, PSD-95, SAPAP1, SAPAP2, Shank3, eIF4A) using both methods 
(Table 2; Fig 6A, B). However, KI/WT ratios for related CaMKAPs (e.g., homer, SAPAP3, 
shank1, shank2 and myosin Va) were essentially unchanged, suggesting that this is not a 
technical artifact (Table 2; Fig. 6I). Although changes in KI/WT ratios may not reflect direct 
effects of a lack of Thr286 autophosphorylation on an interaction with CaMKII, these data 
indicate a broad but selective impact of T286A-KI mutation on synaptic protein-protein 
interactions.
Insights into novel roles of CaMKII
The classical model of a critical role for CaMKII during LTP has been extended by recent 
observations that CaMKII is also involved in different forms of LTD.27, 28 The identification 
of 138 CaMKAPs in the present study suggests novel mechanisms of postsynaptic CaMKII 
signaling that may contribute to these different functions. For example, direct or indirect 
association of Homer and Shank proteins with CaMKII might be important for mGluR1/5-
dependent signaling pathways that are critical for some forms of LTD, especially because 
some of these interactions are sensitive to Thr286 mutation (Fig. 6; Table 2). Thus, the 
current observations provide novel insights into the physiological targeting of CaMKII to 
distinct pathways that mediate diverse synaptic outcomes.
Several of the novel CaMKAPs detected here have been linked to neurological and/or 
psychiatric disorders. For example, BAIAP2 (also known as IRSp53) is highly abundant in 
CaMKII complexes, based on the number of spectral counts detected, and was the only 
CaMKAP predominantly detected in the CaMKIIα gel segment. Moreover, it was the only 
CaMKAP with a significantly decreased KI/WT ratio, estimated by both methods. The 
simplest interpretation of this observation is that BAIAP2 association with CaMKII is 
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decreased in T286A-KI mice, although it is also possible that changes in posttranslational 
modifications of BAIAP2 (e.g. phosphorylation) in T286A-KI synaptic fractions affect the 
electrophoretic mobility of BAIAP2 to decrease the amount of BAIAP2 that essentially co-
migrates with CaMKIIα. Nevertheless, BAIAP2 merits validation as a CaMKAP followed 
by functional analyses because of its known roles in binding PSD95, in regulating actin 
dynamics, filopodia formation, and excitatory synaptic transmission and in modulating 
learning and memory.59–62
Several novel CaMKAPs are involved in mRNA translation, and T286A-KI mutation 
increased relative levels of eIF4A associated with CaMKII (Table 2; Fig 6G). As part of the 
eIF4 translation initiation complex, eIF4A is a D-E-A-D-box RNA helicase.63, 64 
Interestingly, CaMKII regulates the recruitment of eIF4GII to the eIF4 initiation complex,65 
and CaMKII phosphorylation of cytoplasmic polyadenylation element-binding protein 
enhances protein synthesis during LTP.66 Since abnormal protein synthesis is being 
increasingly implicated in neurological and psychiatric disorders,67, 68 our data support 
additional investigation of interactions between CaMKII and the protein synthesis 
machinery.
Synaptic scaffolding proteins implicated in neurological and/or psychiatric disorders were 
also identified as novel synaptic CaMKAPs. For example, the Shank3, Dlgap2, and Syngap1 
genes have been linked to Autism Spectrum Disorder (ASD),69 and specific haplotypes in 
the Dlgap2 gene (SAPAP2) correlate with increased risk for schizophrenia.70 Moreover, 
Shank3 knockout mice exhibit ASD-like behaviors,71 and some ASD-related disorders have 
been linked to abnormal CaMKII signaling (e.g. Angelman syndrome25, 72). Notably, we 
detected increased KI/WT ratios for PSD95, Shank3, and SAPAP1, indicating that these 
interactions are sensitive to Thr286 autophosphorylation (Table 2; Fig 6C–E). Thus, 
regardless of whether CaMKII interacts directly or indirectly with Shank3, SAPAPs, or 
Syngap1, our data suggest that T286A-KI mutation causes significant changes in 
postsynaptic protein architecture. The potential involvement of CaMKII in the physiological 
regulation of these proteins, and in associated pathologies, should be further investigated.
Summary and Conclusions
Prior studies have established that CaMKIIα and CaMKIIβ are critical for many aspects of 
synaptic regulation and behavior, and that CaMKIIα autophosphorylation is a key regulator 
of kinase activity, interactions with other proteins, and subcellular location. However, 
understanding specific molecular mechanisms underlying the diverse synaptic roles of 
CaMKII requires comprehensive information about CaMKII phosphorylation and the 
CaMKII interactome in situ. Here, we used an unbiased semi-quantitative proteomics 
approach to identify biologically relevant phosphorylation sites on both CaMKIIα and 
CaMKIIβ. Our data are consistent with known roles for Thr286/287 and Thr306 
phosphorylation in regulating CaMKII localization. Additional novel sites are differentially 
phosphorylated in the subcellular fractions, and analyses of T286A-KI mice suggest an 
inter-dependence of some phosphorylation events and/or compensatory changes in response 
to mutation. These data suggest a complex physiological interdependence between distinct 
subcellular pools of CaMKII. Using the same unbiased approach, we also identified 138 
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CaMKAPs linked to diverse cellular functions, the majority of which (~100) are 
preferentially associated with synaptic CaMKII holoenzymes. Notably, all the CaMKAPs 
appear to be present at sub-stoichiometric levels relative to CaMKII itself (Fig. 2A), 
consistent with a model in which subpopulations of CaMKII holoenzymes are associated 
with different CaMKAPs to subserve distinct roles. Moreover, interactions with CaMKAPs 
appear to be differentially affected by T286A-KI mutation of CaMKIIα, providing insight 
into molecular changes that may contribute to well-established synaptic and behavioral 
phenotypes of these mice. In combination, these findings should promote future studies to 
identify novel CaMKII-regulated pathways involved in the normal and pathological 
modulation of synaptic physiology, and various forms of learning and memory.
Materials and Methods
DNA constructs and CaMKIIα/β expression
Murine CaMKIIα (Uniprot #P11798) was expressed in Sf9 insect cells.73 Rat CaMKIIβ, 
with an Ala inserted at position 341 in the canonical sequence (Uniprot #P08413), was PCR 
amplified from a construct provided by Dr. L. Redmond Hardy33 and inserted into 
pcDNA3.1 for transfection into HEK293 cells growing in suspension. Thus, residue 
numbering of rat CaMKIIβ used for in vitro studies is increased by one relative to the 
canonical sequence after the Ala insertion site. Both isoforms were purified to ≥95% purity, 
essentially as described.73,74.
In vitro autophosphorylation of CaMKII
Purified recombinant CaMKIIα and CaMKIIβ (5.5 and 2.5 μM, respectively) were incubated 
for 2 min at 30°C in 50 mM HEPES pH 7.5, 2 mM DTT in the absence or presence of 10 
mM Mg(CH3COO)2, 1.5 mM CaCl2, 10 μM calmodulin, 500 μM ATP (basal or Ca2+/CaM 
conditions, respectively). A third sample was first autophosphorylated in the presence of 
Ca2+/calmodulin prior to the addition of EGTA (4 mM final) to allow continued Ca2+-
independent autophosphorylation for 2 min at 30°C (Ca2+/CaM then EGTA; sequential). All 
reactions were terminated by addition of EDTA (25 mM final) and then mixed with 
trichloracetic acid (10% (w/v) final). After incubation on ice for 30 minutes and 
centrifugation (10,000 x g for 15 min), protein pellets were washed by resuspension in cold 
acetone and then re-centrifuged.
Mice
T286A-KI or WT littermates (male: 3–6 months of age) bred from heterozygous breeding 
pairs on a C57BL/6J background (as described previously26) were used for separate 
comparative proteomics analysis. All animal protocols were approved by the Vanderbilt 
Institutional Care and Use Committee.
Immunoprecipitations from whole forebrain fractions
Cytosolic (S1), Triton-soluble membrane (S2), and Triton/deoxycholate soluble synaptic 
(S3) fractions of mouse forebrain75 (~3 mg total protein each) were immunoprecipitated 
using a polyclonal goat CaMKII antibody (5.4 μg) or a goat IgG control (purified from pre-
immune serum by ammonium sulfate precipitation).51, 73 The CaMKII antibody exhibits 
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approximately equivalent sensitivity for purified α, β, γ and δ isoforms of CaMKII in 
immunoblots. Since CaMKII constitutes ~1% of total forebrain protein, each input contains 
~30 μg of CaMKII, likely saturating the antibody during immunoprecipitation, consistent 
with the similar SYPRO Ruby staining intensity for IgG and CaMKII bands in the 
immunoprecipitation lanes in Fig. 2A.
Immunoblotting
Mouse forebrain subcellular fractions were immunoblotted using phospho-Thr286-specific 
(Santa Cruz, 12886-R; 1:1000-1:2000 dilution) and total (Thermo-Pierce, MA1-048; 
1:4000-1:10000 dilution) CaMKIIα antibodies.75
Mass spectrometric analysis
CaMKII and control immunoprecipitates were resolved by SDS-PAGE and stained with 
either SYPRO Ruby (Life Technologies) or colloidal blue stain (Life Technologies). Each 
gel lane was excised in segments, corresponding to the CaMKIIα or CaMKIIβ regions and 
two CaMKAP regions below CaMKIIα and above CaMKIIβ (Fig. 2A). Thus, the gel 
segment containing the highly abundant IgG heavy chain was excluded from all subsequent 
analyses in order to minimize the suppression of MS signals from less abundant proteins. In 
some replicates, only the CaMKIIα and/or CaMKIIβ segments were analyzed for 
phosphorylation sites, whereas other replicates analyzed all four segments to detect co-
precipitating proteins. Gel segments were incubated with 100 mM ammonium bicarbonate, 
pH 8, reduced with 4 mM DTT or TCEP, alkylated with 8 mM iodoacetamide and digested 
overnight with trypsin (10 ng/μl; 37 °C). Extracted peptides were dissolved in 0.1% formic 
acid and resolved using a reverse-phase C18 capillary column (360 μm o.d and 100 μm i.d.) 
packed with Jupiter beads (3-μm, 300 Å; Phenomenex) and equipped with a laser-pulled 
emitter tip using an Eksigent Ultra LC and autosampler. Mobile phases were 0.1% formic 
acid, 99.9% water (solvent A) and 0.1% formic acid, 99.9% acetonitrile (solvent B). The 
elution gradient (500 nl/min) was: 0–10 min, 2% B; 10–50 min, 2–35% B; 50–60 min, 35–
90% B; 60–65 min, 90% B, 65–70 min, 90–2% B, 70–90 min, 2% B. Eluted peptides were 
analyzed on LTQ Orbitrap XL or LTQ Orbitrap Velos mass spectrometers (Thermo 
Scientific) using a data-dependent method with dynamic exclusion enabled. Full scan (m/z 
300–2,000) spectra were acquired with the Orbitrap as the mass analyzer, and the most 
abundant ions (5 on the LTQ Orbitrap XL or 12 on the LTQ Orbitrap Velos) in each MS 
scan were selected for fragmentation via collision-induced dissociation (CID). All tandem 
mass spectra were converted into DTA files using Scansifter and matched to a mouse subset 
of the UniProtKB protein database (also containing reversed (decoy) protein sequences) 
using a custom version of SEQUEST76 on the Vanderbilt ACCRE Linux cluster. The results 
were assembled in Scaffold 3 (Proteome Software) with minimum filtering criteria of 95% 
peptide probability.46 Searches were configured to use variable modifications of cysteine 
carbamidomethylation, methionine oxidation, and serine, threonine, and tyrosine 
phosphorylation. Modifications were validated by manual inspection of raw tandem mass 
spectra using QualBrowser (Xcalibur 2.1.0, Thermo Scientific) (Fig. S1, S2). Peptides 
originating from CaMKIIα and CaMKIIβ were matched to the canonical mRNA splice 
variants in the UniProt database (P11798 and P28652, respectively).
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Spectral Counting from Assembled Scaffold Files
Relative protein abundance in samples from WT and T286A-KI mice was estimated from 
the total number of spectral counts (in all regions of the gel analyzed in a given biological 
replicate) matching a specific protein based on Scaffold files, using both unmodified and 
modified (i.e. cysteine alkylation, methionine oxidation, STY phosphorylation) spectra. The 
global list of ranked proteins, with common contaminants (e.g., keratin) deleted, separated 
by the segment of the parent gel in which they were identified is available online as Table 
S3, which also lists the number of spectral counts detected for each protein in each segment 
and project. For normalizing CaMKAPs from WT and KI synaptic fractions, the total 
number of spectral counts matching a specific CaMKAP was divided by the total number of 
spectral counts matching all of the CaMKII isoforms isolated from the synaptic fraction of 
the same biological replicate.
Extracted Ion Chromatogram (XIC) Analysis
Accurate mass measurements were used to generate extracted ion chromatograms (XICs) 
with a 10 PPM tolerance for non-phosphorylated and phosphorylated peptide pairs, and were 
validated from the MS/MS fragmentation pattern. Monoisotopic m/z values of observed 
precursor ions (across different charge states) were used to generate XICs. The abundance of 
each phosphorylated and non-phosphorylated peptide pair was estimated from areas under 
the curve (AUC) of each XIC. An estimated “percentage phosphorylation” was calculated as 
the ratio of the AUC for the phosphorylated tryptic peptide divided by the sum of AUCs for 
the phosphorylated and non-phosphorylated tryptic peptides (AUCPhospho / (AUCPhospho + 
AUCnon-phospho). AUC based methods can be used to compare relative stoichiometries of 
phosphorylation between different experimental groups,77 although effects of covalent 
modifications on peptide ionization efficiencies and peptide “flyability” suggest caution 
when interpreting absolute values.78 However, even with this caveat, the patterns of absolute 
percentages of CaMKIIα phosphorylation under the in vitro conditions (Fig. 1D, E) are 
consistent with previous data showing that Thr286 is a preferred site of Ca2+/CaM-
dependent autophosphorylation,9–11 whereas Ser314 is a preferred site for Ca2+/CaM-
independent autophosphorylation (Ca2+/CaM followed by EGTA conditions).13, 14 In cases 
where tryptic fragments contains multiple modifications (e.g., oxidation, phosphorylation at 
other sites in the same peptide), or a missed cleavage resulted in the separation of multiple 
tryptic peptides containing the same site-specific modification, the percentage 
phosphorylation was calculated based on the sum of AUCs for all relevant XICs. The 
percentage phosphorylation at a given site in each subcellular fraction from WT or T286A-
KI mice within each biological replicate (processed and analyzed in parallel) was 
normalized to the highest level of phosphorylation detected in a WT subcellular fraction. 
Normalized ratios were then averaged across biological replicates.
AUCs of XICs for precursor ions of a specific tryptic fragment of a CaMKAP were also 
used to compare the abundance of specific CaMKAPs in WT and T286A-KI CaMKII 
holoenzyme samples prepared and analyzed in parallel. For these AUC analyses, we 
carefully selected tryptic fragments lacking any modified (e.g., phosphorylated) versions in 
the Scaffold files. If an XIC was detected and validated by MS/MS in either the WT or KI 
and a corresponding peak of the correct precursor mass and retention time window was 
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detected in the other genotype without an associated MS/MS scan, this peak was used for 
quantification. AUCs for each CaMKAP peptide were expressed as a ratio (KI/WT) and 
normalized to the average KI/WT AUC ratio calculated from 9 unique XICs matching 
CaMKIIα. Thus, the normalized ratio represents the relative abundance of specific tryptic 
precursor ions in samples derived from the two genotypes.
Network Analyses
CaMKAPs (Uniprot IDs) were analyzed using WebGestalt (http://bioinfo.vanderbilt.edu/
webgestalt/). Analyses for Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes 
and Genomes (KEGG) enrichments were performed and are provided either as tables or 
interactive webpages. To identify known or predicted interactions between CaMKAPs, 
Uniprot IDs were input to the STRING database (http://www.string-db.org), which identifies 
interactions based on direct and indirect evidence, including genomic context, high-
throughput experiments, co-expression, and previous knowledge.
Statistics
Comparisons were made using a one-way or two-way ANOVA, as appropriate, followed by 
Tukey’s post-hoc test to compare specific groups. A one-column t-test was used to compare 
KI/WT ratios to a theoretical value of 1 (Fig 6).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Identification of in vitro CaMKIIα and CaMKIIβ phosphorylation sites
A–C. Sequence coverage (red) and phosphorylation-site detection (blue, underlined) in 
purified CaMKIIα or CaMKIIβ following either: A, a control incubation (Basal), B, 
phosphorylation in the presence of Ca2+/calmodulin alone (Ca2+/CaM), or C, sequential 
phosphorylation in the presence of Ca2+/calmodulin and then EGTA (Ca2+/CaM then 
EGTA) (see Methods). D, E. The AUCs of XICs were used to compare relative levels of 
phosphorylation of CaMKIIα at 16 different phosphorylation sites (D) or CaMKIIβ at 15 
different phosphorylation sites (E) in each sample.
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Figure 2. Identification of phosphorylation sites in mouse forebrain CaMKIIα and CaMKIIβ
A. Cytosolic (S1), membrane (S2), and synaptic (S3) fractions were immunoprecipitated 
using control or anti-CaMKII IgG, and immune complexes were analyzed by SDS-PAGE 
followed by staining with Sypro Ruby. B. Semi-quantitative analysis of relative levels of 
CaMKIIα phosphorylation at 6 different sites in each fraction normalized to the highest 
level for each site. The synaptic fraction was selectively enriched for Thr286 
phosphorylation, whereas the cytosolic fraction was selectively enriched for Thr306 
phosphorylation. C. Immunoblot analysis of subcellular fractions confirms that the synaptic 
(S3) fraction is significantly enriched in Thr286 phosphorylated CaMKIIα. D. Semi-
quantitative analysis of relative levels of CaMKIIβ phosphorylation at 6 different sites in 
each fraction normalized to the highest level for each site. The cytosolic fraction was 
selectively enriched for phosphorylation at Ser315 and Thr320/1. *p<0.05; ***p<0.001; 
****p<0.0001; in comparison to the highest level at that site. E. Summary of CaMKII 
phosphorylation sites. Horizontal bars indicate aligned domain structures of the canonical 
CaMKIIα and CaMKIIβ isoforms based on a sequence alignment (accession numbers: 
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P11798 and P28652, respectively). Sequence alignments of selected regions are indicated 
above the bars, whereas CaMKIIβ-specific sequences of the actin-binding domain (ABD) 
are indicated below. All phosphorylation sites detected in this study (in vitro or in vivo) are 
indicated by red dots adjacent to amino acid sequences or by residues in red font adjacent to 
the domain bars. Black dots and fonts indicate additional residues detected in prior global 
phospho-proteomics studies.36–41 Yellow highlighted labels indicate phosphorylation sites 
identified in only one study.
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Figure 3. Effect of T286A-KI mutation on CaMKIIα and CaMKIIβ phosphorylation at other 
sites
Levels of phosphorylation of CaMKIIα (A–E) and CaMKIIβ (F–K) at the indicated sites 
were compared across subcellular fractions isolated in parallel from WT and T286A-KI 
mice. Data are the mean from 4 (A–E) or 3 (F–K) biological replicates after normalization to 
the estimated level in the WT S1 fraction within each replicate. A 2-way ANOVA revealed 
a significant genotype effect on phosphorylation of CaMKIIα at Ser275 (A; F(1,15) = 157.8; 
p<0.0001) and Ser314 (C; F(1,15) = 22.42; p=0.0003) and a significant fractionation effect 
on Thr306 phosphorylation (B; F(2,15) = 35.41; p<0.0001). For CaMKIIβ there were 
significant fractionation and genotype effects and an interaction effect on the 
phosphorylation at Ser315 (E; Fractionation effect (F(2,9) = 153.8, p<0.0001), Genotype 
effect (F(1,9) = 49.4, p<0.0001), Interaction (F(2,9) = 33.55, p<0.0001) and Thr320/
Thr321(F; Fractionation effect (F(2,9) = 58.31, p<0.0001), Genotype effect (F(1,9) = 9.115, 
Baucum et al. Page 24
ACS Chem Neurosci. Author manuscript; available in PMC 2016 April 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
p=0.0145), Interaction (F(2,9) = 6.159, p=0.0206). Significant differences revealed by post-
hoc analyses are coded as follows: *, compared to S1 WT. $, compared to S2 WT. @, 
compared to S3 WT. #, compared to S1 KI. Single, double, triple and quadruple symbols 
indicate p<0.05, p<0.01, p<0.001, and p<0.0001, respectively.
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Figure 4. Comparative levels of CaMKII and CaMKAPs in WT S2 and S3 fractions
A. Fewer total spectral counts derived from all CaMKII isoforms were detected in the S3 
fraction compared to S2 fraction. B. The total number of spectral counts derived from 
proteins other than CaMKII was larger in the S3 fraction that in the S2 fraction. C. More 
proteins other than CaMKII were detected in S3 complexes compared to S2 complexes. 
These data are derived from project A; relative differences between fractions are 
representative of two other independent biological replicates (see Figure S4).
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Figure 5. A CaMKAP interaction map
The STRING-db identifies interactions utilizing genomic context, high-throughput 
experiments, co-expression, and previous knowledge. Default parameters were used to 
generate this map. Associations from multiple sources and/or contexts have thicker lines. 
Proteins were arbitrarily assigned to 14 different groups based on protein function and 
interaction data.
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Figure 6. Effect of T286A-KI mutation of CaMKIIα on the association of selected CaMKAPs 
with CaMKII holoenzymes in the S3 fraction
Relative levels of each CaMKAP in WT and T286A-KI samples were estimated from the 
AUC of XICs for multiple peptides, normalized to the relative levels of CaMKIIα (similarly 
estimated from AUCs for 9 peptides) and then expressed as a ratio (KI/WT). Data from 1 or 
2 independent biological replicates (“projects”) are shown. Each data point is the ratio 
calculated for a single CaMKAP derived peptide, with the mean and S.E.M indicated. A. 
GluN2B, B. GluN1, C. Shank3, D. PSD-95, E. SAPAP1, F. SAPAP2, G. EIF4A, H. 
BAIAP2, I. Myosin Va. Data for each project were compared to a theoretical value of 1 (no 
difference; dashed line) using a one-column t-test. *p<0.05, **p<0.01, ***p<0.001. 
****p<0.0001.
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